CITY THERAPEUTICS, INC.: FMR LLC discloses a stake of more than 5% (Schedule 13G)

FMR LLC disclosed a stake exceeding 5% in City Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000315066-26-002961). The filing signals that Fidelity's parent company has crossed the key 5% beneficial ownership threshold, making it a reportable major shareholder in the biotech. The disclosure does not specify the exact number of shares or the percentage held beyond the 5% minimum. Investors will watch for further 13G amendments or 13D filings that could clarify FMR's position size and intent.